
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is positioned for a successful entry into the market with its lead asset avutometinib showing strong efficacy in combination with defactinib in LGSOC, with potential to be the new standard of care for the indication that has 1,000-2,000 new patients per year. On top of this, the strong biological rationale behind the mechanism of action for avutometinib and its dual RAF/MEK inhibition, coupled with its potential for novel combination regimens, presents further upside for the stock, as demonstrated by the expected strong performance of KRAS G12D inhibitor VS-7375 and its peak sales projections of $292 million. Overall, the company faces the standard risks of the biopharmaceutical industry, but its promising pipeline and strong financials, including its preparation for self-sustaining revenue by 2H26, make it an attractive investment opportunity.
Bears say
Verastem is projected to have a slow and delayed market entry for its VS-7375 drug in the highly competitive space of 2L+ NSCLC and 2L+ PDAC treatment. Additionally, the projected partnership for EU commercialization may lead to a lower sales price for Verastem's drug in that region. Combined with a moderate probability of success and risk-adjusted peak sales, Verastem's financial outlook appears bleak with potentially limited revenue and profitability opportunities.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares